Investigational Drug Details
| Drug ID: | D550 |
| Drug Name: | DPP4 inhibitor |
| Synonyms: | -- |
| Type: | Chemical drug |
| DrugBank ID: | -- |
| DrugBank Description: | -- |
| PubChem ID: | -- |
| CasNo: | -- |
| Repositioning for NAFLD: | No |
| SMILES: | -- |
| InChiKey: | -- |
| Molecular Weight: | -- |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | DPP4 inhibitor |
| Therapeutic Category: | -- |
| Clinical Trial Progress: | Clinical trial on-going (JPRN-UMIN000027304) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0103 | NCT02365233 | Phase 4 | Terminated | Has Results | May 1, 2013 | July 31, 2018 | Details |
| L0546 | JPRN-UMIN000027304 | Not selected | Not Recruiting | Has Results | 15/05/2017 | 17 May 2021 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00255 | 35163991 | Molecules | Sitagliptin Is More Effective Than Gliclazide in Preventing Pro-Fibrotic and Pro-Inflammatory Changes in a Rodent Model of Diet-Induced Non-Alcoholic Fatty Liver Disease. | Details |
| A02827 | 34227216 | Diabetes Obes Metab | Impact of SGLT2 inhibitors in comparison with DPP4 inhibitors on ascites and death in veterans with cirrhosis on metformin. | Details |
| A04245 | 33691757 | Diabetol Metab Syndr | Beneficial effect of omarigliptin on diabetic patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. | Details |
| A12095 | 30605011 | Am J Physiol Gastrointest Liver Physiol | Intestinal TGR5 agonism improves hepatic steatosis and insulin sensitivity in Western diet-fed mice. | Details |
| A12334 | 30510994 | Cell Mol Gastroenterol Hepatol | Dipeptidyl Peptidase 4 Inhibitors Reduce Hepatocellular Carcinoma by Activating Lymphocyte Chemotaxis in Mice. | Details |
| A14182 | 29547706 | Atherosclerosis | Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors. | Details |
| A17234 | 27895822 | World J Diabetes | Linagliptin alleviates fatty liver disease in diabetic db/db mice. | Details |
| A19921 | 26264980 | J Endocrinol | Teneligliptin improves metabolic abnormalities in a mouse model of postmenopausal obesity. | Details |
| A22871 | 24264040 | Int J Mol Sci | Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment. | Details |
| A23956 | 23352496 | J Diabetes Complications | Potential of incretin-based therapies for non-alcoholic fatty liver disease. | Details |
| A30793 | 31768345 | Liver Cancer | Effects of a DPP4 Inhibitor on Progression of NASH-related HCC and the p62/ Keap1/Nrf2-Pentose Phosphate Pathway in a Mouse Model. | Details |
| A47616 | 35053615 | Cancers (Basel) | CD26/DPP4 as a Therapeutic Target in Nonalcoholic Steatohepatitis Associated Hepatocellular Carcinoma. | Details |
| A49488 | 35739957 | Antioxidants (Basel) | Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based Drugs. | Details |